Showing 741 - 760 results of 60,783 for search '(( 50 ((ppm decrease) OR (a decrease)) ) OR ( 5 ((nn decrease) OR (we decrease)) ))', query time: 0.98s Refine Results
  1. 741

    Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination by Cheng Cheng (68821)

    Published 2012
    “…Thus, understanding Ad seropositivity in humans is important to the development of an AIDS vaccine. Here, we analyze the impact of different Ad5-specific neutralizing antibodies on immune function and clinical outcome.…”
  2. 742

    Contribution of direct emissions, seed, compost, other field operations, irrigation, mineral fertilisers, pesticides and transport of inputs to the climate change impact of conservation agriculture popcorn as a function of the percentage of impact allocated to compost: 7.2% (this study), 3.6% (50% decrease), 10.8% (50% increase), and 100% (original life cycle inventory from AGRIBALYSE; Avadi (2020)). by Maria Vittoria Guidoboni (15852669)

    Published 2023
    “…<p>Contribution of direct emissions, seed, compost, other field operations, irrigation, mineral fertilisers, pesticides and transport of inputs to the climate change impact of conservation agriculture popcorn as a function of the percentage of impact allocated to compost: 7.2% (this study), 3.6% (50% decrease), 10.8% (50% increase), and 100% (original life cycle inventory from AGRIBALYSE; Avadi (2020)).…”
  3. 743
  4. 744

    6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

    Published 2025
    “…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”
  5. 745

    6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

    Published 2025
    “…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”
  6. 746

    6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

    Published 2025
    “…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”
  7. 747

    6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

    Published 2025
    “…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”
  8. 748
  9. 749
  10. 750
  11. 751
  12. 752
  13. 753
  14. 754
  15. 755
  16. 756
  17. 757
  18. 758
  19. 759

    Scatter plot for the absolute decrease in CS rates (A) and the relative decrease in CS rates (B) from 2008 to 2016 among hospitals in Guangzhou grouped by their baseline CS rates. by Xiaoyan Xia (560153)

    Published 2019
    “…One circle represents one hospital, with blue (<i>n</i> = 20), green (<i>n</i> = 36), orange (<i>n</i> = 34), and purple (<i>n</i> = 22) representing baseline CS rates of <30%, 30%–39%, 40%–49%, and ≥50%, respectively. The absolute decrease = the CS rate at baseline − the CS rate in Stage 2; the relative decrease = (the CS rate at baseline − the CS rate in Stage 2) ÷ the CS rate at baseline. …”
  20. 760

    DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”